abstract |
The invention provides chimeric antigen receptors containing CD22 antigen binding domains. The invention also relates to nucleic acids, recombinant expression vectors, host cells, antigen-binding fragments and pharmaceutical compositions relating to chimeric antigen receptors. The invention further relates to methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T-cells. |